A hepatitis B-free generation in China: from dream to reality
Rong Fan(Kunming Institute of Botany), Jinlin Hou(Southern Medical University), Zhihong Liu(Chinese Academy of Sciences), Zhihua Liu(Hefei University of Technology), George Lau(Humanity & Health), Xueru Yin(Key Laboratory of Guangdong Province)
Cited by 17
Related Papers
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
|New England Journal of Medicine|2005|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
|The Lancet. Gastroenterology & hepatology|2019|539
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
|Journal of Clinical Oncology|2022|398
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
|Journal of Hepatology|2020|346